DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair, With death on the horizon, nothing will not stop me except God
DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 30 Yrs Exp. in the feld of Organic Chemistry. Serving chemists around the world. Helping them with websites on Chemistry.Millions of hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contribution
n

Sunday, 2 September 2012

SYNTHESIS OF INDOLES

http://onlinelibrary.wiley.com/doi/10.1002/anie.201203657/abstract

Synthesis of Indoles 

Synthesis of Indoles through Highly Efficient Cascade Reactions of Sulfur Ylides and N-(ortho-Chloromethyl)aryl Amides 
Qing-Qing Yang, ET AL
DOI: 10.1002/anie.201203657
Thumbnail image of graphical abstract


A simple procedure carried out under mild conditions allows the direct and efficient synthesis of structurally diverse indoles. This approach involves a cascade reaction of sulfur ylides and N-(ortho-chloromethyl)aryl amides (see scheme).

Monday, 27 August 2012

FROM OPEN ACESS CHEMISTRY-Download ChemDraw Ultra 12.0 for free

Download ChemDraw Ultra 12.0 for free

 

 

 http://www.openaccesschemistry.com/2012/05/download-chemdraw-ultra-120-for-free.html

copy and paste this link on your browser

 

 

enjoy the blog and download

 

 

Monday, 6 August 2012

New carbon-carbon bond in an organic reaction with the original functional groups completely disappearing




http://www.nature.com/nchem/journal/v2/n4/full/nchem.576.html
Mundal et al form a New carbon-carbon bond in an organic reaction with the original functional groups completelely dissapearing, boc protected allyl hydrazone, takes part in an triflimide catalysed sigmatropic reaction with subsequent loss of isobutylene, nitrogen gas and carbondioxide

Monday, 30 July 2012

Stereochemistry of [n,m] Sigmatropic Rearrangements




Stereochemistry of [n,m] Sigmatropic Rearrangements

Basically, [n,m] sigmatropic rearrangements can proceed through a chair or boat  transition state. Only the chair transition state has been observed experimentally though both are suprafacial and are allowed in 4n+2 electron systems.


Chair and boat transition states in [n,m] sigmatropic rearrangements
Fig.1Chair



Fig.2Boat



Examples for sigmatropic rearrangements with a chair transition state

 Fig.3Cope rearrangement

 



Fig.4[3,3] Sigmatropic

               
                        6 Electrons
                   
                        Hückel aromatic
                   
                        Supra-supra


 view animation, 2D Animation of the Cope rearrangement

try copy paste of link below, do not miss out on a beautiful animation


http://www.chemgapedia.de/vsengine/supplement/Vlu/vsc/en/ch/2/vlu/pericyclische_reaktionen/pericyclisch_sigmatrop.vlu/Page/vsc/en/ch/2/oc/reaktionen/formale_systematik/pericyclische_reaktionen/sigmatrop/stereochemie_n_m.vscml/Fragment/0d47d3304bb08cfd9c68c1c3590965d2-19.html


Large substituents similar to their behavior in chair conformations of cyclohexane rings prefer an equatorial configuration in the transition state of [3,3] sigmatropic reactions. Heating S,S-3,4-dimethyl-1,5-hexadiene to approximately 200°C  yields in 90% a product derived from a chair transition state with equatorial methyl groups.  The product arising from a diaxial conformation is formed in only 10% yield. Obviously, the reaction does not proceed through the boat transition state.

Sunday, 29 July 2012

Enantiomeric Ibuprofen via Environmentally Benign Selective Crystallization

 Ibuprofen was developed by the Boots Group, a pharmacy chain in the United Kingdom, in the 1950’s-1960s. It was discovered by Stewart Adams (along with John Nicholson, Andrew RM Dunlop, Jeffrey Bruce Wilson & Colin Burrows). The Boots group originally licensed Ibuprofen to two large drug companies. The first was Whitehall Laboratories (who sold the product as Advil) and the second was Upjohn who used Bristol-Meyers to market their product “Nuprin”. Boots held the patent until 1985 along with the rights to market it until 1986. Afterwards new products entered the market creating multiple new “generic” brands.





Selective crystallization of ibuprofen/lysinate from 1 mol of (R,S)-(racemic) ibuprofen and ≤0.5 mol of (S)-lysine in aqueous ethanol affords either (S)-(+)-ibuprofen/(S)-lysinate or (R)-ibuprofen/(S)-lysinate (in preponderance) depending on the crystallization conditions. The previously unreported temperature selective diastereo-recognition (TSD) provides simple and efficient means to prepare either enantiomer of ibuprofen from (R,S)-ibuprofen utilizing the same commercially available inexpensive resolving agent, (S)-lysine. The unwanted enantiomeric ibuprofen could be recovered from the mother liquor and racemized by a simple, relatively waste-free thermal process. This racemization method when utilized in conjunction with the selective crystallization technology provides a simple, efficient, and eco-friendly means to prepare (S)-(+)-ibuprofen lysinate in an overall essentially quantitative yield. This technology also incorporates the fundamental principle of atom economy (via direct production of the preferred pharmaceutical salt of (S)-lysine). Abstract Image 

Temperature Selective Diastereo-Recognition (TSD):  Enantiomeric Ibuprofen via Environmentally Benign Selective Crystallization

 see also
http://onlinelibrary.wiley.com/doi/10.1002/aic.11087/abstract;jsessionid=D60C69E3DB7266BE103A2875A7FEA6C5.d02t03?deniedAccessCustomisedMessage=&userIsAuthenticated=false
 copy paste on browser

read more at
 http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0104-66322006000300003
copy paste on browser

Sunday, 22 July 2012

Citalopram/Escitalopram Oxalate, Isolation & Synthesis of Novel Impurities, Emcure paper


Citalopram

Citalopram  brand names: CelexaCipramil) is an antidepressantdrug of the selective serotonin reuptake inhibitor (SSRI) class. It has U.S. Food and Drug Administration (FDA) approval to treat major depression, and is prescribed off-label for a number of anxiety conditions.


Escitalopram (trade names NexitoAnxiset-E (India), Lexapro,CipralexSeroplexLexamilLexamEntactLosita(Bangladesh) Reposil (Chile)), is an antidepressant of theselective serotonin reuptake inhibitor (SSRI) class. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults and children over 12 years of age with major depressive disorder and generalized anxiety disorder. Escitalopram is the (S)-stereoisomer (enantiomer) of the earlier Lundbeck drugcitalopram

Citalopram/Escitalopram Oxalate: Isolation & Synthesis of Novel Impurities

READ AT
Emcure Pharmaceuticals Ltd, R & D Centre, Pimpri, Pune -411018, India

Abstract Image

During process optimization of Escitalopram oxalate novel impurities, 6 and 7 were observed, which were isolated and characterized, and the proposed structure was confirmed by chemical synthesis. Investigation of the cause of impurities formation improved the yield and purity of the drug product during the bulk API synthesis

SPECTROSCOPIC DATA IS AVAILABLE IN SUPPORTING INFORMATION FILE IN THE PAPER

ARTEMETHER, A FORCE AGAINST MALARIA




Artemether  
is an antimalarial for the treatment of multi-drug resistant strains offalciparum malaria. It is combined with Lumefantrine and sold by Novartis under the brand names Riamet and Co-Artem.


It is a methyl ether derivative of artemisinin, which is a peroxide lactone isolated from theChinese antimalarial plant, Artemisia annua. It is also known as dihydroartemisinin methyl ether, but its correct chemical nomenclature is (+)-(3-alpha,5a-beta,6-beta,8a-beta, 9-alpha,12-beta,12aR)-decahydro-10-methoxy-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin.


Artemether is highly effective against the blood schizonts of both malarial parasites P. falciparum and P. vivax. It is applied in combination with lumefantrine in clinical treatments of malaria
World Health Organization guidelines for the treatment of uncomplicatedfalciparum malaria recommend the use of this artemisinin-based combination therapy, and approved by Swissmedic in December 2008 and recently approved by the United StatesFood and Drug Administration.

Abstract Image

READ AT
http://pubs.acs.org/doi/abs/10.1021/op300037e

A 70% overall yield from the two-step conversion of naturally or synthetically derived artemisinin to pure β-artemether is obtained. This corresponds to a usage factor of 1.35 kg of artemisinin needed to produce 1 kg of β-artemether, compared to the current industry average of 1.59 kg.